Slone Partners Places Phil Paik, Ph.D., as Vice President, Platform Development, at Molecular Assemblies

Share Article

Experienced industry leader will advance breakthrough technology into a commercial platform

Molecular Assemblies
“Dr. Paik is an experienced industry leader who brings a track record of success over many years,” said Slone Partners President Tara Kochis-Stach.

Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of Phil Paik, Ph.D., as Vice President, Platform Development, at Molecular Assemblies, Inc. In his new role, Dr. Paik’s deep expertise in microfluidics and product development will be applied in advancing Molecular Assemblies’ breakthrough enzymatic DNA synthesis technology into a commercial platform.

Dr. Paik has more than 16 years of experience in technology innovation and platform development. Prior to joining Molecular Assemblies, he served as Associate Director of Engineering at Illumina, where he led the fluidics architecture development for both instrument and integrated cartridge-based platforms, and managed the fluidics engineering group within product development.

“Dr. Paik is an experienced industry leader who brings a track record of success over many years,” said Slone Partners President Tara Kochis-Stach. “His extensive knowledge and innovative foresight will be a wonderful addition to the strong Molecular Assemblies leadership team as the company moves into the next exciting phase of commercial development of its transformational enzymatic DNA synthesis technology.”

"We are excited to welcome Phil to Molecular Assemblies, where he will lead the development of our commercial enzymatic DNA synthesis platform," said Michael J. Kamdar, President and CEO of Molecular Assemblies. "Phil's deep expertise and experience in advancing microfluidic solutions to transform novel technologies into robust, commercial products will be invaluable as we empower enzymatic DNA synthesis to deliver rapid innovation for a broad range of industries, including synthetic biology, therapeutics, vaccines, agriculture, and DNA data storage."

"I'm impressed by the enormous potential of enzymatic DNA synthesis to transform industries with the reliable, affordable, and sustainable production of long, high-quality DNA, at scale," said Dr. Paik. "Molecular Assemblies not only has a proprietary technology position but also has an amazing team, dedicated partnerships, and supportive investors that propel the company to a leadership position in the field of enzymatic DNA synthesis."

Dr. Paik began his career as a founding member of Advanced Liquid Logic, where he was responsible for the development of key functionalities and manufacturability of a novel digital microfluidic platform for lab-on-a-chip applications. He also served as senior microfluidics design engineer at ICx Technologies (acquired by FLIR Systems) under a division focused on the platform integration of high-performance assays for biodefense applications.

ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing and diverse life sciences organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT MOLECULAR ASSEMBLIES
Molecular Assemblies, Inc. is a private biotech company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high-quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies' technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego. For more information, please visit http://www.molecularassemblies.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Doug Gavel
Visit website